Hepion Pharmaceuticals, Inc. (HEPA)
Largest Insider Buys in Sector
HEPA Stock Price History Chart
HEPA Stock Performance
About Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor …
Insider Activity of Hepion Pharmaceuticals, Inc.
Over the last 12 months, insiders at Hepion Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Hepion Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Hepion Pharmaceuticals, Inc. have bought $82,443 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,500 shares for transaction amount of $7,625 was made by Wijngaard Peter (director) on 2023‑11‑27.
List of Insider Buy and Sell Transactions, Hepion Pharmaceuticals, Inc.
| 2023-11-27 | director | 2,500 0.0602% | $3.05 | $7,625 | -55.03% | |||
| 2023-11-24 | director | 2,500 0.058% | $3.09 | $7,725 | -56.45% | |||
| 2023-09-19 | director | 1,000 0.0252% | $5.64 | $5,640 | -61.75% | |||
| 2023-09-18 | CEO and Director | 1,600 0.0419% | $5.60 | $8,960 | -59.96% | |||
| 2023-09-15 | CEO,CSO and Director | 1,600 0.0429% | $5.40 | $8,640 | -57.14% | |||
| 2023-09-15 | director | 2,000 0.0556% | $5.60 | $11,201 | -57.14% | |||
| 2021-02-18 | CEO and Director | 20,000 0.0017% | $2.00 | $40,000 | -29.09% | |||
| 2021-02-18 | Chief Financial Officer | 10,000 0.0009% | $2.00 | $20,000 | -29.09% | |||
| 2021-02-16 | director | 10,000 0.0009% | $2.20 | $22,000 | -29.73% | |||
| 2020-12-18 | director | 20,000 0.2035% | $1.91 | $38,200 | -13.40% | |||
| 2020-12-08 | CEO and Director | 25,000 0.2327% | $1.58 | $39,418 | -2.86% | |||
| 2020-12-02 | director | 7,000 0.0696% | $1.53 | $10,710 | +6.92% | |||
| 2020-12-01 | director | 12,000 0.1247% | $1.66 | $19,920 | +3.03% | |||
| 2020-11-25 | Chief Financial Officer | 4,500 0.0477% | $1.62 | $7,290 | +7.59% | |||
| 2017-06-20 | CFO | 20,000 0.0017% | $0.65 | $13,000 | -43.47% | |||
| 2016-02-18 | Chief Executive Officer | 10,000 0.0018% | $1.00 | $10,000 | +8.65% | |||
| 2015-11-30 | Chief Executive Officer | 500 <0.0001% | $2.15 | $1,075 | -51.77% | |||
| 2015-11-23 | Chief Executive Officer | 2,500 0.0004% | $1.64 | $4,100 | -38.42% | |||
| 2014-03-04 | director | 4,393 0.0015% | $1.49 | $6,546 | +12.91% |
Insider Historical Profitability
| Foster Robert T | CEO and Director | 50470 0.7253% | $0.50 | 4 | 0 | <0.0001% |
| Cavan John T | Chief Financial Officer | 14800 0.2127% | $0.50 | 3 | 0 | <0.0001% |
| SAPIRSTEIN JAMES | Chief Executive Officer | 13000 0.1868% | $0.50 | 3 | 0 | |
| JACOB GARY S | director | 12059 0.1733% | $0.50 | 1 | 0 | +3.03% |
| Wijngaard Peter | director | 9501 0.1365% | $0.50 | 6 | 0 | <0.0001% |
Institutional Investor Ownership
| Armistice Capital Llc | $971,100.00 | 6.73 | 390,000 | -6.7% | -$69,720.00 | <0.01 | |
| The Vanguard Group | $391,826.00 | 2.71 | 157,360 | -1.86% | -$7,432.64 | <0.0001 | |
| BlackRock | $206,555.00 | 1.43 | 82,954 | 0% | +$0 | <0.0001 | |
| Geode Capital Management | $96,724.00 | 0.67 | 38,833 | +11.24% | +$9,773.77 | <0.0001 | |
| State Street | $39,033.00 | 0.27 | 15,676 | 0% | +$0 | <0.0001 |